RxDoctor Payments Data

Christopher Brown, MD

Gastroenterology · Stockbridge, GANPI 1194715813

Payments from drug & device makers

$13,779in general payments, 2019–2025

Across 782 payments — averaging $17.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Gilead$1K
  • Johnson & Johnson$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$981
  • Ironwood Pharmaceuticals, Inc$555
  • plus $5K from 23 others

What the payments were for

  • Consulting fees$130%
  • Food & beverage$13,68699%
  • Education$801%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,779 in reported general payments places this provider in the 85th percentile of 492 gastroenterology providers in Georgia.

See all gastroenterology providers in Georgia

Medicare billing

Part B allowed, 2024
$153,849
Medicare patients
407
Services billed
2,554

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin14$44,407
LinzessLinaclotide30$15,874
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates141$9,900
TrulancePlecanatide13$6,997
Colesevelam Hcl21$4,647
Sucralfate51$4,500
Dicyclomine Hcl148$2,740
Dexlansoprazole DrDexlansoprazole15$2,721
Entecavir11$2,353
Pantoprazole Sodium298$2,014
CholestyramineCholestyramine (With Sugar)21$1,972
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl56$949
Omeprazole82$703
Famotidine102$655
Azathioprine11$601

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$2,204$51,40427 claims
AbbVieLinzess$2,915$15,87430 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 492 gastroenterology providers in Georgia.

Other gastroenterology in Stockbridge

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →